Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia

This publication has 68 references indexed in Scilit:

• Identification of a novel WT1‐derived peptide which induces human leucocyte antigen‐A24‐restricted anti‐leukaemia cytotoxic T lymphocytes
  British Journal of Haematology, 2002
• The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy
  Leukemia, 2001
• Cytokine-regulated expression of survivinin myeloid leukemia
  Blood, 2001
• Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
  Blood, 2000
• Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules
  Leukemia, 2000
• Induction of Minor Histocompatibility Antigen HA-1–Specific Cytotoxic T Cells for the Treatment of Leukemia After Allogeneic Stem Cell Transplantation
  Blood, 1999
• Dendritic cells and the control of immunity
  Nature, 1998
• Peptides derived from the whole sequence of BCR‐ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes
  European Journal of Immunology, 1997
• T-cell immunity to the joining region of p210BCR-ABL protein.
  Proceedings of the National Academy of Sciences, 1992
• The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid Gene
  Science, 1986